Tissue Collection for Studies of Lymph Cancer
NCT01676805
Recruiting
Background: - Lab studies help researchers better understand cancer biology. This information may lead to new methods for diagnosing or treating cancer. To develop these studies, researchers want to collect samples from people with cancer or precancer conditions of the lymph system. These conditions include multiple myeloma, different types of lymphoma, and adult leukemia/lymphoma. The samples collected will include blood, urine, bone marrow, and tumor and skin tissue. Objectives: - To collec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland +1 locations
Conditions: Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphomatoid Granulomatosis, Leukemia-Lymphoma, Adult T-Cell
Register for Updates
NIAID Centralized Sequencing Protocol
NCT03206099
Recruiting
Background: Genetic testing called "sequencing" helps researchers look at DNA. Genes are made of DNA and are the instructions for our bodies to function. We all have thousands of genes. DNA variants are differences in genes between two people. We all have lots of variants. Most are harmless and some cause differences like blue or brown eyes. A few variants can cause health problems. Objective: To understand the genetics of immune disorders various health conditions, as well as outcomes of cli... Read More
Gender:
ALL
Ages:
Between 1 day and 100 years
Trial Updated:
04/10/2025
Locations: Children's National Health System, Washington, District of Columbia +1 locations
Conditions: Atopy, Primary Immunodeficiency, Autoimmunity, Autoinflammation
Register for Updates
Markers of Osteoporosis in Cystic Fibrosis
NCT03921060
Recruiting
Main Study Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan, micro CT, and blood collection. Denosumab (Prolia) Sub study Approximately 10 adult subjects with CF who participated in the main study and have results indicating bone disease will receive treatment with Denosumab for up to 5 years. They will be asked to return annually for repeat DEXA scans, micro CT, and blood collection.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/10/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Cystic Fibrosis
Register for Updates
Dietary Behavior Intervention in African Americans at Risk for Cardiovascular Disease
NCT04305431
Recruiting
Background: The risk of heart disease among African Americans is still common despite a greater understanding of the disease and better approaches to managing it. Healthy cooking and eating patterns can help reduce the risk of heart disease. But things like access to grocery stores and knowledge of good nutrition can affect these healthy patterns. Researchers want to see if community-based programs can help. Objective: To learn about the cooking behaviors of African American adults at risk fo... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/10/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Diet, Cooking
Register for Updates
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
NCT04819841
Recruiting
This study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynamic data.
Gender:
ALL
Ages:
Between 12 years and 40 years
Trial Updated:
04/10/2025
Locations: Lucile Packard Children's Hospital, Palo Alto, California +2 locations
Conditions: Sickle Cell Disease
Register for Updates
BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
NCT05003843
Recruiting
The objective of this study is to demonstrate the safety and efficacy of the Indigo Aspiration system for percutaneous mechanical thrombectomy in a population presenting with obstruction due to deep vein thrombosis (DVT) who are eligible for treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Sharp Grossmont, La Mesa, California +40 locations
Conditions: Deep Vein Thrombosis, DVT
Register for Updates
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
NCT05242965
Recruiting
This phase II trial tests whether CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine (STEMVAC) works to shrink tumors in patients with stage IV non-small cell lung cancer. STEMVAC targets specific immunogenic proteins that help lung cancer cells to grow. STEMVAC is made up of deoxyribonucleic acid (DNA), which is a natural substance in every living organism. DNA acts like a blueprint that tells all the cells in your body how to function. The DNA used in this study contains instructions fo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: VA Puget Sound Health Care System, Seattle, Washington +1 locations
Conditions: Stage IV Lung Cancer AJCC v8, Lung Non-Small Cell Carcinoma
Register for Updates
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
NCT05489705
Recruiting
This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are receiving mavacamten, receiving other treatment for obstructive HCM, or not receiving treatment for obstructive HCM due to intolerance or failure of prior treatment. United States Sub-Study: The purpose of this study is to evaluate the safety of mavacamt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Alaska Heart Institute, Anchorage, Alaska +97 locations
Conditions: Obstructive Hypertrophic Cardiomyopathy
Register for Updates
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections
NCT05639647
Recruiting
The purpose of this study is to evaluate how Aztreonam (ATM) and Avibactam (AVI) are processed in pediatric participants. This study also aims to understand participant safety and effects in pediatric participants. The study is seeking participants who are: * 9 months to less than 18 years of age * Hospitalized * Suspected/known to have a gram-negative infection * Receiving intravenous (iv, given directly into a vein) antibiotics * Being treated for complicated infections of various body parts... Read More
Gender:
ALL
Ages:
Between 9 months and 17 years
Trial Updated:
04/10/2025
Locations: Rady Children's Hospital, San Diego, California +32 locations
Conditions: Gram-negative Bacterial Infections
Register for Updates
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
NCT05765500
Recruiting
This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. The drugs are already standard treatment for people with prostate cancer, and the drugs will be used as described in their label. The names of the study drugs involved in this study are: * Leuprolide (type of ADT) * Relugolix (type of ADT)
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +2 locations
Conditions: Prostate Cancer, Prostatic Neoplasms
Register for Updates
A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
NCT05904496
Recruiting
This is a First in Human (FIH) Phase 1, multicenter, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-30813 as monotherapy or in combination with tislelizumab in participants with advanced or metastatic solid tumors. The study will be conducted in 2 parts: Phase 1a dose escalation and Phase 1b dose expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Hackensack University Medical Center, Hackensack, New Jersey +7 locations
Conditions: Advanced Solid Tumors
Register for Updates
Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation
NCT06093867
Recruiting
Background: Stem cell transplants (called hematopoietic stem cell transplantation, or HSCT) are used to treat various diseases. But when the cells for this procedure are donated by someone other than the person who receives the HSCT ( allogeneic HSCT ), the recipient has an increased risk of lung inflammation and scarring. This happens when their immune cells attack healthy lung cells. In this natural history study, researchers will look for the best ways to detect developing lung inflammations... Read More
Gender:
ALL
Ages:
Between 5 years and 70 years
Trial Updated:
04/10/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Register for Updates